|Videos|July 22, 2021

Vyluma pipeline focuses on refractive error

Vyluma, which recently spun off from Nevakar, has a robust pipeline for potential therapies addressing refractive error. Navneet Puri, PhD, the company’s founder, chairman, and CEO, offers additional insights.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.


Latest CME